{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:42:08Z","timestamp":1794530528208,"version":"4.9.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.neurot.2024.e00435","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T21:35:50Z","timestamp":1724448950000},"page":"e00435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?"],"prefix":"10.1016","volume":"21","author":[{"given":"Ashley L.","family":"Harkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajakta P.","family":"Ambegaokar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Keeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neurot.2024.e00435_bib1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nn.3161","article-title":"Immune surveillance in the central nervous system","volume":"15","author":"Ousman","year":"2012","journal-title":"Nat Neurosci"},{"issue":"9270","key":"10.1016\/j.neurot.2024.e00435_bib2","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(00)04904-7","article-title":"An overview of the immune system","volume":"357","author":"Parkin","year":"2001","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nri.2016.13","article-title":"Immunological memory: lessons from the past and a look to the future","volume":"16","author":"Farber","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00435_bib4","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J\u00a0Clin Investig"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2\u2013mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00435_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00435_bib7","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 can induce innate and adaptive immune response in the primate eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00435_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J\u00a0Pediatr"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00435_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/d41573-021-00164-x","article-title":"Gene therapy community grapples with toxicity issues, as pipeline matures","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"10.1016\/j.neurot.2024.e00435_bib10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib11","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol Ther"},{"issue":"13\u201314","key":"10.1016\/j.neurot.2024.e00435_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2024.040","article-title":"Innate immune sensing of adeno-associated virus vectors","volume":"35","author":"Cao","year":"2024","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0952-7915(00)00180-1","article-title":"The cell biology of antigen presentation in dendritic cells","volume":"13","author":"Th\u00e9ry","year":"2001","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1365-2249.2002.01774.x","article-title":"Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells","volume":"127","author":"Barker","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.neurot.2024.e00435_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.omtm.2023.06.001","article-title":"Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation","volume":"30","author":"Corti","year":"2023","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00435_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.omtm.2018.09.003","article-title":"Adeno-associated virus neutralizing antibodies in large animals and their impact on brain intraparenchymal gene transfer","volume":"11","author":"Wang","year":"2018","journal-title":"Mol Ther - Methods Clin Dev"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib17","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.ymthe.2023.03.032","article-title":"Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy","volume":"31","author":"Logan","year":"2023","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00435_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jgm.885","article-title":"Immune responses to AAV in a phase I study for Canavan disease","volume":"8","author":"McPhee","year":"2006","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.neurot.2024.e00435_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658399","article-title":"Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions","volume":"12","author":"Weber","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2024.e00435_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","article-title":"Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper","volume":"26","author":"Yang","year":"2022","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00435_bib21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions","volume":"5","author":"Basner-Tschakarjan","year":"2014","journal-title":"Front Immunol"},{"issue":"13\u201314","key":"10.1016\/j.neurot.2024.e00435_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/hum.2023.227","article-title":"Role of FoxP3+ regulatory T cells in modulating immune responses to AAV gene therapy","volume":"35","author":"Melero","year":"2024","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00435_bib23","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1172\/JCI70314","article-title":"Human Treg responses allow sustained recombinant adeno-associated virus\u2013mediated transgene expression","volume":"123","author":"Mueller","year":"2013","journal-title":"J\u00a0Clin Investig"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00435_bib24","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ymthe.2017.03.029","article-title":"5 Year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency","volume":"25","author":"Mueller","year":"2017","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00435_bib26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1016\/j.neurot.2024.e00435_bib27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00435_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal Neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00435_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00435_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00435_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ni1078","article-title":"Elaborate interactions between the immune and nervous systems","volume":"5","author":"Steinman","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.neurot.2024.e00435_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annual Review of Immunology [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00435_bib33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1582-4934.2010.01010.x","article-title":"Basic mechanisms of neurodegeneration: a critical update","volume":"14","author":"Jellinger","year":"2010","journal-title":"J\u00a0Cell Mol Med"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.nurt.2010.05.014","article-title":"Microglial activation and chronic neurodegeneration","volume":"7","author":"Lull","year":"2010","journal-title":"Neurotherapeutics"},{"issue":"13","key":"10.1016\/j.neurot.2024.e00435_bib35","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1523\/JNEUROSCI.4363-08.2009","article-title":"Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals","volume":"29","author":"Wake","year":"2009","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00435_bib36","article-title":"AAV targeting of glial cell types in the central and peripheral nervous system and relevance to human gene therapy","volume":"13","author":"O'Carroll","year":"2021","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s42003-022-04200-3","article-title":"Development of microglia-targeting adeno-associated viral vectors as tools to study microglial behavior in vivo","volume":"5","author":"Okada","year":"2022","journal-title":"Commun Biol"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00435_bib38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.gt.3301925","article-title":"Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors","volume":"10","author":"Cucchiarini","year":"2003","journal-title":"Gene Ther"},{"issue":"35","key":"10.1016\/j.neurot.2024.e00435_bib39","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302997120","article-title":"Targeted evolution of adeno-associated virus capsids for systemic transgene delivery to microglia and tissue-resident macrophages","volume":"120","author":"Young","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00435_bib40","doi-asserted-by":"crossref","first-page":"350","DOI":"10.5607\/en.2017.26.6.350","article-title":"AAV-mediated astrocyte-specific gene expression under human ALDH1L1 promoter in mouse thalamus","volume":"26","author":"Koh","year":"2017","journal-title":"Exp Neurobiol"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00435_bib41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41434-019-0075-6","article-title":"Astrocyte-selective AAV gene therapy through the endogenous GFAP promoter results in robust transduction in the rat spinal cord following injury","volume":"26","author":"Griffin","year":"2019","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00435_bib43","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.23648","article-title":"The blood\u2013brain barrier in health and disease","volume":"72","author":"Daneman","year":"2012","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2045-8118-9-23","article-title":"Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation","volume":"9","author":"Luissint","year":"2012","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib45","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1038\/s41467-023-39038-8","article-title":"The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson's disease","volume":"14","author":"Jacquet","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00435_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbi.2023.05.009","article-title":"Brain resident memory T cells rapidly expand and initiate neuroinflammatory responses following CNS viral infection","volume":"112","author":"Ayasoufi","year":"2023","journal-title":"Brain Behav Immun"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00435_bib47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41577-021-00652-6","article-title":"B\u00a0cells in central nervous system disease: diversity, locations and pathophysiology","volume":"22","author":"Jain","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib48","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12964-023-01324-9","article-title":"Natural killer cells in the central nervous system","volume":"21","author":"Ning","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11481-012-9414-8","article-title":"Immune heterogeneity in neuroinflammation: dendritic cells in the brain","volume":"8","author":"Colton","year":"2013","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.fmre.2023.01.012","article-title":"Skull and vertebral bone marrow in central nervous system inflammation","volume":"4","author":"Ren","year":"2024","journal-title":"Fundam Res"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nri1130","article-title":"Three or more routes for leukocyte migration into the central nervous system","volume":"3","author":"Ransohoff","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00435_bib52","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal gene therapy for giant axonal Neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib53","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1084\/jem.20142290","article-title":"A\u00a0dural lymphatic vascular system that drains brain interstitial fluid and macromolecules","volume":"212","author":"Aspelund","year":"2015","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib54","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib55","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2017.02.004","article-title":"Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs","volume":"25","author":"Mack","year":"2017","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00435_bib56","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/mus.25658","article-title":"Long-term effects of systemic gene therapy in a canine model of myotubular myopathy","volume":"56","author":"Elverman","year":"2017","journal-title":"Muscle Nerve"},{"issue":"220","key":"10.1016\/j.neurot.2024.e00435_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007523","article-title":"Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy","volume":"6","author":"Childers","year":"2014","journal-title":"Sci Transl Med"},{"issue":"35","key":"10.1016\/j.neurot.2024.e00435_bib58","doi-asserted-by":"crossref","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib59","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/hmg\/ddq514","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","author":"Dominguez","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00435_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1208\/s12248-023-00814-5","article-title":"Evaluation of cellular immune response to adeno-associated virus-based gene therapy","volume":"25","author":"Gorovits","year":"2023","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00435_bib61","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","article-title":"Establishment and dysfunction of the blood-brain barrier","volume":"163","author":"Zhao","year":"2015","journal-title":"Cell"},{"issue":"9579","key":"10.1016\/j.neurot.2024.e00435_bib62","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00435_bib63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.25450","article-title":"Magnetic resonance imaging\u2013guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease","volume":"85","author":"Christine","year":"2019","journal-title":"Ann Neurol"},{"issue":"20","key":"10.1016\/j.neurot.2024.e00435_bib64","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson diseaseSYMBOL","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00435_bib65","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.neurot.2024.e00435_bib66","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson diseaseSYMBOL","volume":"70","author":"Eberling","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib67","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons","volume":"12","author":"Pearson","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib68","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib69","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90133","article-title":"Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease","volume":"2","author":"Niethammer","year":"2017","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib70","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00435_bib71","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A\u00a0phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease","volume":"18","author":"Muramatsu","year":"2010","journal-title":"Mol Ther"},{"issue":"134","key":"10.1016\/j.neurot.2024.e00435_bib72","doi-asserted-by":"crossref","first-page":"134ra61","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic l-amino acid decarboxylase deficiency","volume":"4","author":"Hwu","year":"2012","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","article-title":"Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial","volume":"1","author":"Chien","year":"2017","journal-title":"Lancet Child Adolesc Heal"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00435_bib74","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00435_bib75","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2\u2013neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib76","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.24436","article-title":"Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial","volume":"78","author":"Olanow","year":"2015","journal-title":"Ann Neurol"},{"issue":"18","key":"10.1016\/j.neurot.2024.e00435_bib77","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","article-title":"Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients","volume":"80","author":"Bartus","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00435_bib78","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/brain\/awaa020","article-title":"Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease","volume":"143","author":"Chu","year":"2020","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib79","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/hum.2015.134","article-title":"Long-term safety of patients with Parkinson's disease receiving rAAV2-neurturin (CERE-120) gene transfer","volume":"27","author":"Marks","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00435_bib80","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","article-title":"A\u00a0phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease","volume":"10","author":"Rafii","year":"2014","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101217","article-title":"Preexisting antibody assays for gene therapy: considerations on patient selection cutoffs and companion diagnostic requirements","volume":"32","author":"Braun","year":"2024","journal-title":"Mol Ther - Methods Clin Dev"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib82","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-associated viral vector (serotype 2)\u2013nerve growth factor for patients with alzheimer disease: a randomized clinical trial","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib83","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/brain\/awy331","article-title":"Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency","volume":"142","author":"Kojima","year":"2019","journal-title":"Brain"},{"issue":"17\u201318","key":"10.1016\/j.neurot.2024.e00435_bib84","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1089\/hum.2022.170","article-title":"Redosing adeno-associated virus gene therapy to the central nervous system","volume":"33","author":"McElroy","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00435_bib85","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum Gene Ther"},{"issue":"572","key":"10.1016\/j.neurot.2024.e00435_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5413","article-title":"Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2","volume":"12","author":"Sondhi","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00435_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.655478","article-title":"Cell-mediated immunity to NAGLU transgene following intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome","volume":"12","author":"Gougeon","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib88","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, efficient, and reproducible gene therapy of the brain in the dog models of sanfilippo and hurler syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib90","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/ijms25021050","article-title":"Delivery of adeno-associated virus vectors to the central nervous system for correction of single gene disorders","volume":"25","author":"Daci","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2024.e00435_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.965089","article-title":"Delivering gene therapy for mucopolysaccharide diseases","volume":"9","author":"Wood","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib92","first-page":"169","article-title":"Huntington's disease clinical trials corner: august 2023","volume":"12","author":"Estevez-Fraga","year":"2023","journal-title":"J\u00a0Huntingt Dis"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib93","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib94","first-page":"77","article-title":"Immune responses observed to AAV gene therapy for the treatment of GM2 gangliosides","volume":"31","author":"Flotte","year":"2023","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00435_bib95","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood\u2013brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00435_bib96","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf"},{"issue":"14","key":"10.1016\/j.neurot.2024.e00435_bib97","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"issue":"6701","key":"10.1016\/j.neurot.2024.e00435_bib98","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002112","article-title":"Targeting AAV vectors to the central nervous system by engineering capsid\u2013receptor interactions that enable crossing of the blood\u2013brain barrier","volume":"21","author":"Huang","year":"2023","journal-title":"PLoS Biol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat Neurosci"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00435_bib101","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41565-023-01419-x","article-title":"Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain","volume":"18","author":"Chuapoco","year":"2023","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00435_bib102","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/biology12020186","article-title":"AAV engineering for improving tropism to the central nervous system","volume":"12","author":"Ghauri","year":"2023","journal-title":"Biology"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00435_bib103","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00435_bib104","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/jmg.2008.057950","article-title":"Congenital heart disease is a feature of severe infantile spinal muscular atrophy","volume":"45","author":"Rudnik-Sch\u00f6neborn","year":"2008","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00435_bib106","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib107","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib108","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00435_bib109","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00435_bib110","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Retracted article: rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"17\u201318","key":"10.1016\/j.neurot.2024.e00435_bib111","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis confirms deaths of two patients treated with gene therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib112","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib113","first-page":"6","article-title":"Clinical dose-response relationship and safety profile of rAAVrh8-HexA\/HexB","volume":"31","author":"Flotte","year":"2023","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00435_bib114","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11901-023-00624-5","article-title":"Hepatotoxicity in adeno-associated viral vector gene therapy","volume":"22","author":"Jagadisan","year":"2023","journal-title":"Curr Hepat Rep"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00435_bib115","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12974-019-1567-4","article-title":"Plasma neurofilament light chain and amyloid-\u03b2 are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease","volume":"16","author":"Chatterjee","year":"2019","journal-title":"J\u00a0Neuroinflammation"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T01:12:07Z","timestamp":1727140327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1878747924001211"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00435","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00435"}}